Clinical TrialJun 4, 2026, 09:46 AM
MAIA Biotechnology's THIO-104 Phase 3 trial enrolls 29 patients
AI Summary
MAIA Biotechnology provided an update on its pivotal Phase 3 THIO-104 trial for ateganosine, a novel telomere-targeting therapy for advanced non-small cell lung cancer (NSCLC). The trial has dosed 29 patients across 34 sites in 6 countries, with a target of up to 100 patients by year-end and an interim analysis expected in 2027. Ateganosine, which has US FDA Fast Track designation, showed a median overall survival of 17.8 months in Phase 2, significantly higher than the 5.8 months for standard chemotherapy, and targets a projected $70 billion global NSCLC market by 2030.
Key Highlights
- 29 patients have been dosed in the pivotal Phase 3 THIO-104 trial.
- The trial is active across 34 sites in 6 foreign countries.
- MAIA is targeting up to 100 patients by year-end for the Phase 3 study.
- An interim analysis for the THIO-104 trial is expected in 2027.
- Phase 2 THIO-101 trial showed a median overall survival of 17.8 months.
- Standard 3L NSCLC chemotherapy has an expected survival of 5.8 months.
- Ateganosine has been granted US FDA Fast Track designation for 3L NSCLC.
- The global NSCLC treatment market is projected to reach $70 billion by 2030.
Price Impact
More from MAIA